SSG
AQST icon

Summit Securities Group’s Aquestive Therapeutics AQST Stock Holding History

Summit Securities Group’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,666
Closed -$23.7K – 783
2024
Q4 		$23.7K Buy
+6,666
New +$30.7K ﹤0.01% 360

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return

Summit Securities Group's AQST Position: Q1 2025 in Review

Summit Securities Group sold out of Aquestive Therapeutics (AQST) in Q1 2025, closing a stake of 6,666 shares — an estimated $23.7K sold.

Summit Securities Group first reported a position in AQST in Q4 2024 and held it in 1 quarter. The position peaked at $23.7K in Q4 2024. 121 funds tracked by Wall St. Rank hold AQST as of Q1 2025.

  • Summit Securities Group reported no remaining Aquestive Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Summit Securities Group sold 6,666 Aquestive Therapeutics shares in Q1 2025, an estimated $23.7K.
  • Summit Securities Group first reported a position in Aquestive Therapeutics in Q4 2024 and held it in 1 quarter.
  • Summit Securities Group's Aquestive Therapeutics position peaked at $23.7K in Q4 2024.
  • 121 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2025.

Based on Summit Securities Group's 13F filing for Q1 2025, filed 13 May 2025.